Medicine Information

Nipotin

Name: Nipotin
Brand: Nipotin

Solution for Injection3000 IU/0.3 mLHematopoietic AgentsATC: B03XA01

Generic Name

Erythropoietin Alfa

Manufacturer

Square Pharmaceuticals Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
nipotin 3000 iu injection	৳ 1,400.00	N/A

Description

Overview of the medicine

Nipotin 3000 IU Injection contains Erythropoietin Alfa, a recombinant human erythropoietin. It is used to treat anemia associated with chronic kidney disease, cancer chemotherapy, and certain other conditions by stimulating red blood cell production in the bone marrow.

Uses & Indications

Anemia of Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis.

Anemia in cancer patients receiving myelosuppressive chemotherapy.

Anemia in zidovudine-treated HIV-infected patients.

Reduction of allogeneic red blood cell transfusions in surgical patients.

Dosage

Adults

Dosage varies significantly based on indication and patient's hemoglobin levels. Typically initiated at 50-150 IU/kg three times weekly (CKD) or 150-300 IU/kg once weekly (chemotherapy-induced anemia) via subcutaneous or intravenous injection. Doses are adjusted to maintain target hemoglobin levels (e.g., 10-12 g/dL).

Elderly

No specific dose adjustment recommended for elderly patients, but careful monitoring is advised.

Renal_impairment

Used to treat anemia in renal impairment; dosage is individualized based on response.

How to Take

Administer subcutaneously or intravenously. Subcutaneous administration is generally preferred for ease of use and for patients not on hemodialysis. Do not shake. Inspect visually for particulate matter and discoloration prior to administration.

Mechanism of Action

Erythropoietin Alfa stimulates erythropoiesis by interacting with the erythropoietin receptor on progenitor cells in the bone marrow, promoting their proliferation and differentiation into mature red blood cells.

Pharmacokinetics

Onset

Hematological response usually observed within 2-6 weeks.

Excretion

Eliminated mainly through urine (small amount) and primarily by receptor-mediated uptake and degradation.

Half life

Terminal half-life is approximately 4-13 hours after IV administration and longer (around 24 hours) after SC administration.

Absorption

Following subcutaneous administration, peak serum concentrations are reached within 12-18 hours. Bioavailability is approximately 30-50%.

Metabolism

Primarily metabolized by non-specific proteolytic degradation.

Side Effects

Contraindications

Uncontrolled hypertension
Pure Red Cell Aplasia (PRCA) unrelated to erythropoietin therapy
Known hypersensitivity to erythropoietin alfa or any component of the formulation

Drug Interactions

General

No significant drug-drug interactions are generally expected, but close monitoring of iron status and blood pressure is important.

Immunosuppressants

May affect erythropoietin response.

Storage

Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.

Overdose

Overdose can lead to polycythemia (excessive red blood cells) and associated complications like increased blood viscosity, potentially leading to thrombotic events. Management involves phlebotomy to reduce hemoglobin and hematocrit to target levels.

Pregnancy & Lactation

Pregnancy Category C. Use only if potential benefit outweighs potential risk to the fetus. It is unknown if erythropoietin alfa is excreted in human milk; caution should be exercised when administered to a nursing woman.

Side Effects

Contraindications

Uncontrolled hypertension
Pure Red Cell Aplasia (PRCA) unrelated to erythropoietin therapy
Known hypersensitivity to erythropoietin alfa or any component of the formulation

Drug Interactions

General

No significant drug-drug interactions are generally expected, but close monitoring of iron status and blood pressure is important.

Immunosuppressants

May affect erythropoietin response.

Storage

Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.

Overdose

Pregnancy & Lactation

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

1 pre-filled syringe of 3000 IU/0.3 mL6 pre-filled syringes of 3000 IU/0.3 mL

Shelf Life

Typically 24-36 months when stored under recommended conditions.

Availability

Hospitals, Pharmacies

Approval Status

Approved

Patent Status

Generic available, original patent expired

WHO Essential Medicine

Yes

Clinical Trials

Extensively studied in numerous clinical trials demonstrating efficacy in treating anemia associated with CKD, cancer chemotherapy, and other conditions. Ongoing post-marketing surveillance and studies continue to refine usage.

Lab Monitoring

Hemoglobin and Hematocrit (weekly until stable, then regularly)
Iron studies (transferrin saturation, ferritin)
Blood pressure monitoring

Doctor Notes

Monitor hemoglobin levels closely and adjust dose to avoid levels >11 g/dL.
Assess iron status regularly and supplement as needed.
Educate patients on symptoms of thrombotic events.
Not a substitute for red blood cell transfusions in acute settings requiring immediate correction of severe anemia.

Patient Guidelines

Do not shake the vial or syringe.
Report any signs of blood clots (e.g., chest pain, shortness of breath, sudden numbness) immediately.
Follow all instructions regarding dose and administration.
Keep all appointments with your doctor for lab tests.

Missed Dose Advice

If a dose is missed, administer it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose.

Driving Precautions

Nipotin is not known to impair the ability to drive or operate machinery. However, if you experience dizziness or seizures, you should avoid such activities.